Advertisement

Topics

FDA Grants Priority Review to Insmed’s ALIS in NTM Lung Disease Caused by MAC

14:24 EDT 17 May 2018 | Speciality Pharma Journal

BRIDGEWATER, N.J., May 16, 2018 (GLOBE NEWSWIRE) — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for adult patients with nontuberculous mycobacterial (NTM) …

Original Article: FDA Grants Priority Review to Insmed’s ALIS in NTM Lung Disease Caused by MAC

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Insmed’s ALIS in NTM Lung Disease Caused by MAC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...